Expression Of Il-33 In Colorectal Cancer And Its Association With Clinical Features

Tumor immunotherapy has strong potential worldwide. IL-33 mostly acts as a danger signal from damaged cells, and has recently been discovered as a influencing factor in the process of tumor immunity. The aim of the study is to discover the expression of IL-33 in colorectal cancer (CRC) and its association with clinical features and prognosis. We found that the positive expression rate of IL-33 in tumor tissues was significantly lower than that in peritumoral tissues (38.78% vs. 63.75%, Pearson chi(2) = 10.989 P = 0.001). In addition, serum IL-33 levels in moderate or poor differentiation CRC cases were significantly higher than that in well differentiation cases. Serum IL-33 level in colon cancer cases was also significantly higher than that in rectal cancer cases (P < 0.01). Moreover, that combination of serum IL-33, CEA and CA19-9 may improve diagnostic efficiency for colorectal cancer. In conclusion, IL-33 may associate with tumor progress in CRC, and showed improved value in CRC diagnosis.